The volume of vaccine analytical literature is notable (the journal Vaccine alone having published 231 trials on diVerent vaccines between 1983 and 1994 1 ). However, to date little attention has been paid to summarising and evaluating its significance in the assessment of vaccine quality (defined as eYcacy, eVectiveness, eYciency, safety, and acceptability). Quality assessment is important as vaccines are a widely used preventive technology, vaccination programmes are mostly publicly funded, and decisions to immunise whole populations must be made on the best available evidence, especially if such practice is regulated by law. Additionally the current array of vaccines is likely to be augmented considerably in scope and variety by new vaccines imposing a resource burden on society. Such a burden, set against the backdrop of increased health care costs, will necessitate discrimination of funding of preventive programmes. Discrimination should be partly based on the best available evidence of vaccine eVectiveness and safety, of the social burden of the target disease and of the ability of the vaccine to prevent that burden developing. 2 The Cochrane Vaccines Field (CVF) was founded to facilitate the gathering of evidence on vaccines and their eVects (such as ability to prevent the target disease, short and long term safety and eYciency in making best use of scarce resources) into systematic reviews. Trials alone are unlikely to answer questions related to the long term eVects of vaccines and the incidence of rare side eVects (the mean length of study duration of 59 reports of randomised controlled trials and CCTs on hepatitis B vaccines was 270 days (median 420 days)). 1 Inevitably important aspects of vaccine quality will have to be assessed also by the means of available observational studies, either of cohort or case-control design.
The economics of vaccinology suVer from several methodological problems, such as a variable quality of studies and an "inverse incidence law" whereby the higher the global impact of the target disease the lower the number of its economic evaluations. 3 To increase knowledge on the economics of vaccines the CVF has promoted two systematic reviews of economic evaluations of vaccines (hepatitis B and influenza) and is developing possible methods to sum up economic information.
To assist the process of prioritisation a valid and generalisable measure of vaccine eVect on public health would be desirable. Despite its limits the calculation of the burden of disease in DALYs (Disability Adjusted Life Years) seems a promising way foward. 4 For this reason the available DALY data for preventable disease have been used in table 1, which summarises the available knowledge on the eVectiveness and economics of vaccines and current gaps in evidence-based vaccinology.
